drugset / Trial / NCT01433666
Roflumilast and Cognition
Phase 2
Completed
22 enrolled
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedCrossoverTriple-blindBasic science
Summary
The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.
Timeline
- Start
- 2011-09
- Primary completion
- 2012-07
- Completion
- 2013-09
Publications
- Results Heckman PRA, Van Duinen MA, Blokland A, Uz T, Prickaerts J, Sambeth A. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial. Psychopharmacology (Berl). 2018 Jan;235(1):301-308. doi: 10.1007/s00213-017-4770-y. Epub 2017 Nov 3.
- Results Van Duinen MA, Sambeth A, Heckman PRA, Smit S, Tsai M, Lahu G, Uz T, Blokland A, Prickaerts J. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology. 2018 Mar 15;131:31-38. doi: 10.1016/j.neuropharm.2017.12.019. Epub 2017 Dec 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Roflumilast | Small molecule | 100 ug | — |
| Subject | Roflumilast | Small molecule | 300 ug | — |
| Subject | Roflumilast | Small molecule | 1000 ug | — |